Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

806
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
806
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

677
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
677
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).

ESMO real world data and digital oncology·2026
Same author

The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

NPJ breast cancer·2026
Same author

Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study.

ESMO real world data and digital oncology·2026
Same author

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Discrepancy between mammographic and pathological sizing of screen-detected DCIS: Risk factors and impact on ipsilateral recurrence rates.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Proton Beam Therapy for Intracranial Germ Cell Tumors in Pediatric, Adolescent, and Young Adult Patients: A Single-Center Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset.

R Pathak1, M Wallington2, C Saunders3

  • 1University of Manchester, Manchester, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 22, 2017
PubMed
Summary
This summary is machine-generated.

The Systemic Anti-Cancer Therapy dataset accurately tracks patient outcomes for cancer drug treatments. This resource is valuable for analyzing survival data in patients receiving chemotherapy.

Keywords:
CDFCancer Drug FundSACTSystemic Anti-Cancer Therapy datasetcetuximabcolorectal

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Area of Science:

  • Oncology
  • Health Informatics

Background:

  • The Systemic Anti-Cancer Therapy dataset is a crucial resource for cancer research.
  • Accurate patient outcome data is essential for evaluating treatment efficacy.

Purpose of the Study:

  • To audit the accuracy of the Systemic Anti-Cancer Therapy dataset.
  • To assess its utility for analyzing patient outcomes in metastatic colorectal cancer treated with monoclonal antibodies.

Main Methods:

  • Data accuracy audit of the Systemic Anti-Cancer Therapy dataset.
  • Analysis of patient outcomes for those receiving Cancer Drug Fund-funded monoclonal antibodies.

Main Results:

  • The Systemic Anti-Cancer Therapy dataset demonstrates accuracy for outcome analysis.
  • The dataset is suitable for evaluating treatments like monoclonal antibodies for metastatic colorectal cancer.

Conclusions:

  • The Systemic Anti-Cancer Therapy dataset is a valuable resource for rapid survival outcome analysis.
  • It supports the evaluation of chemotherapy treatments and targeted therapies.